HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Guangzhou Baiyunshan Pharmaceutical Holdings (874.HK) - Conservative About the Outlook

Oral COVID-19 Antivirals and the Impact on China

China Healthcare Weekly (Dec.31)-1st State-Level Device Policy,TCM Guideline,TCM Rally Unsustainable

Microport Scientific (853.HK) - The Favorable and the Unfavorable Aspects

2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties

Sino Biopharmaceutical (1177.HK) - The Business, The Concerns, The Insights on Biopharma Valuation

Gravity Works As WeWork Doesn't; Now Plan B

Equity Capital Markets

HTDK Medical Holdings / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/htdk-medical-holdings-limited" target="_blank" data-smartkarma-citation="entities:34111:1" rel="noopener">HTDK Medical Holdings</a> is a leading cross-border commercial solutions platform in China offering specialized market entrance and penetration solutions for high-value medical devices, with particular strength in serving global brands.</li>
<li>This insights mainly analyzed the industry characteristics, the business and the concerns of the Company.</li>
<li>For HTDK, policy risk is the biggest risk. So, how to make breakthrough is a problem HTDK has to solve. </li>
</ul>



HTDK Medical Holdings is a leading cross-border commercial solutions platform in China offering specialized market entrance and penetration solutions for high-value medical devices, with particular strength in serving global brands.
This insights mainly analyzed the industry characteristics, the business and the concerns of the Company.
For HTDK, policy risk is the biggest risk. So, how to make breakthrough is a problem HTDK has to solve. 


Pre-IPO HTDK Medical Holdings - Policy Risk Is the Biggest Uncertainty